National Cancer Institute; Notice of Meeting, 62750 [2024-16949]
Download as PDF
<![CDATA[
62750
Federal Register / Vol. 89, No. 148 / Thursday, August 1, 2024 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Average time
per response
(in hours)
Total annual
burden hour
eIDP .................................................................................................................
Exit Survey Part 1 ............................................................................................
Exit Survey Part 2 ............................................................................................
150
150
150
1
1
1
2
30/60
30/60
300
75
75
Total ..........................................................................................................
150
150
3
450
Dated: July 25, 2024.
Cesar E. Perez-Gonzalez,
Training Director, National Eye Institute,
National Institutes of Health.
[FR Doc. 2024–16917 Filed 7–31–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the President’s Cancer Panel.
The meeting will be held as a virtual
meeting and will be open to the public
as indicated below. Individuals who
plan to view the virtual meeting and
need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting. The meeting can be accessed
by clicking on the links below.
ddrumheller on DSK120RN23PROD with NOTICES1
Number of
responses per
respondent
Name of Committee: President’s Cancer
Panel.
Date: September 12, 2024.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: Developing and Retaining a
Robust and Diverse Cancer Workforce:
Challenges and Opportunities Across the
National Cancer Program.
Place: National Institutes of Health, 31
Center Drive, Building 31, Room 11A48,
Rockville, MD 20850 (Virtual Meeting),
Access to Meeting: https://nci.rev.
vbrick.com/#/webcasts/presidentscancer
panel-meet1.
Date: September 13, 2024.
Time: 11:00 a.m. to 5:30 p.m.
Agenda: Developing and Retaining a
Robust and Diverse Cancer Workforce:
Challenges and Opportunities Across the
National Cancer Program.
Place: National Institutes of Health, 31
Center Drive, Building 31, Room 11A48,
Rockville, MD 20850 (Virtual Meeting),
Access to Meeting: https://nci.rev.
vbrick.com/#/webcasts/presidentscancer
panel-meet2.
Contact Person: Samantha L. Finstad,
Ph.D., Executive Secretary, President’s
Cancer Panel, Office of the Director, National
Cancer Institute, NIH, 31 Center Drive, Room
VerDate Sep<11>2014
17:17 Jul 31, 2024
Jkt 262001
11A30B, MSC 2590, Bethesda, MD 20892,
240–276–6460, samantha.finstad@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/pcp/index.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–16949 Filed 7–31–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines) using
Urine and the laboratories currently
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) publishes a notice
listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities
(IITFs) in the Federal Register during
the first week of each month, in
accordance with Section 9.19 of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
Section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any
laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/drug-testing-resources/
certified-lab-list.
HHS separately notifies Federal
agencies of the laboratories and IITFs
currently certified to meet the standards
of the Mandatory Guidelines using
Urine and of the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23,
E:\FR\FM\01AUN1.SGM
01AUN1
]]>Agencies
[Federal Register Volume 89, Number 148 (Thursday, August 1, 2024)]
[Notices]
[Page 62750]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16949]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the President's Cancer
Panel.
The meeting will be held as a virtual meeting and will be open to
the public as indicated below. Individuals who plan to view the virtual
meeting and need special assistance or other reasonable accommodations
to view the meeting, should notify the Contact Person listed below in
advance of the meeting. The meeting can be accessed by clicking on the
links below.
Name of Committee: President's Cancer Panel.
Date: September 12, 2024.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: Developing and Retaining a Robust and Diverse Cancer
Workforce: Challenges and Opportunities Across the National Cancer
Program.
Place: National Institutes of Health, 31 Center Drive, Building
31, Room 11A48, Rockville, MD 20850 (Virtual Meeting), Access to
Meeting: https://nci.rev.vbrick.com/#/webcasts/presidentscancerpanel-meet1.
Date: September 13, 2024.
Time: 11:00 a.m. to 5:30 p.m.
Agenda: Developing and Retaining a Robust and Diverse Cancer
Workforce: Challenges and Opportunities Across the National Cancer
Program.
Place: National Institutes of Health, 31 Center Drive, Building
31, Room 11A48, Rockville, MD 20850 (Virtual Meeting), Access to
Meeting: https://nci.rev.vbrick.com/#/webcasts/presidentscancerpanel-meet2.
Contact Person: Samantha L. Finstad, Ph.D., Executive Secretary,
President's Cancer Panel, Office of the Director, National Cancer
Institute, NIH, 31 Center Drive, Room 11A30B, MSC 2590, Bethesda, MD
20892, 240-276-6460, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/pcp/index.htm, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: July 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-16949 Filed 7-31-24; 8:45 am]
BILLING CODE 4140-01-P
